Blood and Lymphatic Cancer-Targets and Therapy最新文献

{"title":"Enzymatic Laccase Nanoreactors Induce Apoptosis in MOLT-4-ALL Cells and Activate Prodrugs in a Synergetic Effect.","authors":"Carlos A Medrano-Villagómez, Elizabeth Loredo-García, Jahaziel Gasperin-Bulbarela, Rafael Vazquez-Duhalt","doi":"10.2147/BLCTT.S576292","DOIUrl":"10.2147/BLCTT.S576292","url":null,"abstract":"<p><strong>Introduction: </strong>The search for novel cancer treatment strategies is of great interest. Recently, it has been reported that laccases from various sources exhibit anti-tumor effects. In addition, the use of nanometric platforms for delivering therapeutic agents at the cellular level is a promising approach for efficient cancer treatment. In this work, the cytotoxicity of <i>Coriolopsis gallica</i> laccase on human leukemia MOLT-4 cells was evaluated.</p><p><strong>Methods: </strong>Laccase was nanoconfined in a virus-like nanoparticle (VLPs) of the brome mosaic virus (BMV), and both free and nanoconfined preparations were evaluated the activation of prodrugs. The cytotoxicity was evaluated by neutral red to obtain the dose-response curve. Afterward, the death cell and mechanisms were characterized using flow cytometry of combinations of laccase (free and VLPs) with prodrugs (Doxorubicin, Irinotecan, and Procarbazine).</p><p><strong>Results: </strong>Laccase alone showed an apoptotic effect at a concentration of 0.35 μM (IC₂₀), with a 49% of apoptotic cells at 24 hours. This effect was enhanced by the presence of doxorubicin (63.79%), irinotecan (43.44%), and procarbazine (53.27%) in the presence of both the free version (Lac) and the nano-encapsidated version (VLP-saLac). A similar effect was observed for the necroptosis population. Finally, the CI (Combination Index) was estimated by two different models, and the synergistic effect on cell death was confirmed.</p><p><strong>Discussion: </strong>The laccase pro-apoptotic effect in MOLT-4 cells has been demonstrated, increasing cytotoxicity by activating prodrugs in both free and nanoconfined forms.</p>","PeriodicalId":42368,"journal":{"name":"Blood and Lymphatic Cancer-Targets and Therapy","volume":"16 ","pages":"576292"},"PeriodicalIF":3.2,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13134575/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147821883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Defining High-Risk Disease Biology in Multiple Myeloma: A Narrative Review.","authors":"Mohammad Aljumaa, Hasan Hamam Refai, Yogesh Chawla, Wilson I Gonsalves","doi":"10.2147/BLCTT.S586948","DOIUrl":"10.2147/BLCTT.S586948","url":null,"abstract":"<p><p>Although modern therapies have significantly improved survival, multiple myeloma (MM) remains incurable and biologically heterogeneous, resulting in substantial variability in treatment response and outcomes. Effective risk stratification is therefore critical to guide therapy intensity, predict relapses, and inform prognosis. This review critically examines the current biological determinants of high-risk MM and their implications for treatment intensification, selection of novel therapeutic agents, and stratified clinical trial enrollment. High-risk MM is driven by three major biological determinants: (1) molecular and genomic abnormalities, including high-risk IgH translocations, del(17p), TP53 mutation, gain(1q), and high-risk gene expression signatures; (2) increased proliferative capacity, with an elevated plasma-cell S-phase fraction identifying a subgroup with markedly inferior survival independent of conventional staging; and (3) extramedullary dissemination biology, reflected by circulating tumor cells and soft-tissue extramedullary disease, both associated with marrow independence, clonal evolution, and poor outcomes. The 2024 IMS/IMWG framework integrates the genomic aspects of these biological markers and certain clinical factors into a more precisely defined disease. Complementing baseline classification, dynamic risk stratification using measurable residual disease (MRD) provides real-time prognostic refinement across the treatment course. Future advances will rely on comprehensive molecular profiling and AI-driven data integration to enable precision-guided treatment based on individualized disease biology.</p>","PeriodicalId":42368,"journal":{"name":"Blood and Lymphatic Cancer-Targets and Therapy","volume":"16 ","pages":"586948"},"PeriodicalIF":3.2,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13134554/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147821830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venetoclax Plus Hypomethylating Agents for Treatment-Naïve Myelodysplastic Syndromes with Increased Blasts: A Prospective Multicenter Cohort Study.","authors":"Na Zhao, Lijun Zhu, Xing Hu, Juan Tong, Hongfeng Ge, Li Ye, Xijun Zhu, Can Gai, Yuhu Feng, Lei Zhang, Li Wang, Guangyu Sun, Lei Xue, Xiaoyu Zhu, Changcheng Zheng","doi":"10.2147/BLCTT.S592550","DOIUrl":"10.2147/BLCTT.S592550","url":null,"abstract":"<p><strong>Purpose: </strong>Evidence supporting venetoclax combined with hypomethylating agents (HMAs) in treatment-naïve myelodysplastic syndromes with increased blasts (MDS-IB), a biologically aggressive subset with high risk of leukemic transformation, remains lacking. We conducted a prospective, multicenter cohort study to evaluate the efficacy and safety of venetoclax plus HMAs in newly diagnosed MDS-IB.</p><p><strong>Patients and methods: </strong>In this prospective, multicenter, single-arm trial conducted at six hospitals in China (August 2022-September 2024), 43 newly diagnosed adults with MDS-IB received venetoclax (ramp-up to 400 mg on days 1-14) plus azacitidine or decitabine in 28-day cycles. Dose adjustments were made for cytopenias, infections, or drug interactions. Primary endpoints were overall response rate (ORR), duration of response (DoR), and safety. Secondary endpoints included overall survival (OS) and transformation to acute myeloid leukemia. The study was registered in the Chinese Clinical Trial Registry (registration number: [ChiCTR2200055204]).</p><p><strong>Results: </strong>The ORR was 74.4% (95% CI, 58.8-86.5%), comprising 34.4% complete remission (CR), 59.4% marrow CR (mCR), and 6.3% partial response (PR). Among the thirty-two patients who got ORR, the median DoR was 8.1 months (range, 0.9-29.0). The 6-, 12-, and 24-month DoR rates were 68.8% (95% CI, 49.7-81.8%), 53.2% (95% CI, 33.7-69.4%), and 47.7% (95% CI, 27.8-65.1%), respectively. Median OS was 12.8 months, with 12- and 24-month OS rates of 62.4% (95% CI, 46.1-75.1%) and 49.3% (95% CI, 32.2-64.3%), respectively. Grade 3/4 neutropenia/febrile neutropenia occurred in 60% (26/43), and pneumonia in 16% (7/43). The median interval between cycles was 59 days (range 33-113), mainly due to hematologic toxicity.</p><p><strong>Conclusion: </strong>Venetoclax plus HMAs demonstrated promising clinical activity with manageable toxicity in newly diagnosed MDS-IB, supporting further prospective evaluation of this combination in treatment-naïve patients with increased-blast MDS.</p><p><strong>Trial registration: </strong>Chinese Clinical Trial Registry, ChiCTR2200055204, https://www.chictr.org.cn/index.html.</p>","PeriodicalId":42368,"journal":{"name":"Blood and Lymphatic Cancer-Targets and Therapy","volume":"16 ","pages":"592550"},"PeriodicalIF":3.2,"publicationDate":"2026-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13123550/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147784486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Value of the Aggregate Inflammation Systemic Index (AISI) in Patients with Diffuse Large B-Cell Lymphoma: A Multicenter Retrospective Study.","authors":"Xicheng Chen, Linyu Huang, Qiming Zhang, Xing Xing, Shuo Zhang, Chunling Wang, Ling Wang, Ziyuan Shen, Wei Sang","doi":"10.2147/BLCTT.S571663","DOIUrl":"10.2147/BLCTT.S571663","url":null,"abstract":"<p><strong>Background: </strong>The aggregate index of systemic inflammation (AISI, calculated as neutrophil count × monocyte count × platelet count/lymphocyte count) reflects systemic inflammatory status; however, its prognostic role in diffuse large B-cell lymphoma (DLBCL) remains underexplored. This study aimed to investigate the prognostic value of AISI in DLBCL.</p><p><strong>Methods: </strong>A total of 1332 DLBCL patients (median age 62 years; 52.3% male) were included in this study. Patients were stratified based on AISI quartiles, and a cut-off value was determined using restricted cubic splines (RCS) analysis. The associations between AISI and Overall survival (OS) were assessed using Kaplan-Meier analysis and Cox proportional hazards models.</p><p><strong>Results: </strong>Higher AISI levels were associated with adverse clinical features, including advanced Ann Arbor stage, poor performance status, and higher-risk categories of both the IPI and the NCCN-IPI. RCS analysis revealed a nonlinear relationship between AISI and OS, with an inflection point at 261.33. Kaplan-Meier analysis demonstrated that patients with AISI > 261.33 had significantly worse OS compared to those with AISI ≤ 261.33 (<i>P</i> = 0.003). Similarly, patients in the Q4 group had poorer OS than those in the lowest two quartiles (Q1-Q2) (<i>P</i> = 0.008). In fully adjusted Cox proportional hazards models (adjusted for age, sex, Ann Arbor stage, LDH, ECOG performance status, BMI, albumin, B symptoms, bone marrow involvement, central nervous system involvement, and liver/spleen involvement), high AISI level (> 261.33) were associated with increased mortality risk (<i>HR</i> = 1.28, 95% CI: 1.04-1.57, <i>P</i> = 0.018). Subgroup analyses indicated that the prognostic impact of AISI was particularly evident among patients classified as low risk by conventional prognostic systems.</p><p><strong>Conclusion: </strong>Elevated AISI was associated with inferior OS in DLBCL patients and may potentially serve as a prognostic biomarker.</p>","PeriodicalId":42368,"journal":{"name":"Blood and Lymphatic Cancer-Targets and Therapy","volume":"16 ","pages":"571663"},"PeriodicalIF":3.2,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13050976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147634621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Crosstalk Between FOXN3 and E2F5 Reveals a Novel Tumor Suppressive Pathway in Acute Myeloid Leukemia via MAPK Signaling: Implications for Potential Future Targeted Therapy.","authors":"Jinjing Zhang, Qiao Jiang, Tong Liu, Hong Li, Ying Liang, Xianglan Lu, Hui Pang, Shibo Li, Yan Li, Rui Zhang","doi":"10.2147/BLCTT.S571966","DOIUrl":"10.2147/BLCTT.S571966","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the mechanism of FOXN3 in acute leukemia.</p><p><strong>Methods: </strong>ChIP-seq experiments were performed using FOXN3-specific antibodies to identify FOXN3 target genes in acute myeloid leukemia (AML). Bioinformatics analyses were conducted to determine the enrichment of biological processes and pathways related to cell cycle regulation and apoptosis among the target genes. The transcriptional regulation of the gene of interest was confirmed through RT-qPCR, Western blotting, and luciferase reporter assays. Additionally, we examined the significance of FOXN3 on the prognosis of AML patients. Functional studies were performed following the knockdown and overexpression of the target gene in AML cells. Furthermore, we investigated the interaction between FOXN3 and the target gene by co-transfecting AML cells with lentiviruses overexpressing the target gene, followed by examinations of downstream signaling pathways through RNA-seq and pathway enrichment analyses.</p><p><strong>Results: </strong>FOXN3 regulates E2F5 expression, leading to decreased mRNA and protein levels of E2F5 upon FOXN3 overexpression, though additional factors may contribute to this repression. Notably, E2F5 expression was elevated in AML patients and cell lines, correlating with unfavorable clinical outcomes. Functional investigations revealed that E2F5 functions as an oncogene in AML, promoting cell proliferation, inhibiting apoptosis, and influencing cell cycle progression. Co-transfection experiments demonstrated that E2F5 could counteract the proliferation-inhibitory effect of FOXN3. Additionally, FOXN3 was found to modulate the MAPK signaling pathway and its downstream target, EZH2.</p><p><strong>Conclusion: </strong>This study reveals a novel regulatory axis involving FOXN3 and E2F5 in AML. FOXN3 acts as a tumor suppressor by regulating E2F5 and modulating downstream MAPK signaling pathways.</p>","PeriodicalId":42368,"journal":{"name":"Blood and Lymphatic Cancer-Targets and Therapy","volume":"16 ","pages":"571966"},"PeriodicalIF":3.2,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13032739/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147575676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health Disparities in Acute Myeloid Leukemia Patients Undergoing Treatment with Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2.","authors":"Manuel R Espinoza-Gutarra, Brooke A Jarrett, Xiaoliang Wang, Anosheh Afghahi, Sejong Bae","doi":"10.2147/BLCTT.S559759","DOIUrl":"10.2147/BLCTT.S559759","url":null,"abstract":"<p><p>Acute Myeloid Leukemia (AML) is a common hematologic neoplasm in adults and usually carries a grim prognosis. Therapy has traditionally consisted of intensive chemotherapy; however, recent advances have led to the development of Tyrosine Kinase Inhibitors (TKI) as Targeted Therapies for subtypes carrying certain mutations. While the clinical impact of these therapies has been well described, there have been no studies looking at clinical disparities among different racial/ethnic groups receiving these therapies. We leveraged an EHR-derived database to evaluate real-world outcomes in patients receiving TKIs for AML. Our study found no significant differences between real-world Event Free Survival (rwEFS) and real world Overall Survival (rwOS) across patients of different racial/ethnic groups, this suggests that when patients have access to targeted therapy outcomes across different racial/ethnic groups become more equitable.</p>","PeriodicalId":42368,"journal":{"name":"Blood and Lymphatic Cancer-Targets and Therapy","volume":"16 ","pages":"559759"},"PeriodicalIF":3.2,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12990797/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147475727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Construction and Validation of an N7-Methylguanosine-Related Prognostic Model for Acute Myeloid Leukemia.","authors":"Lina Wang, Ming Li, Yaming Xi","doi":"10.2147/BLCTT.S575337","DOIUrl":"10.2147/BLCTT.S575337","url":null,"abstract":"<p><strong>Purpose: </strong>Increasing evidence suggests the involvement of N7-methylguanosine (m7G) in cancer biology. However, its role in acute myeloid leukemia (AML) remains unclear. Herein, bioinformatics approaches were used to obtain insights for AML risk stratification and treatment.</p><p><strong>Patients and methods: </strong>Data from TCGA-LAML, GSE114868, and GSE37642 were analyzed. Differentially expressed genes from GSE114868 were intersected with key module genes identified via weighted gene co-expression network analysis. The identified genes underwent univariate and multivariate Cox regression analyses and machine learning to identify prognostically relevant m7G-related genes (m7G-RGs). Moreover, a prognostic risk model was built and validated, and its association with immune infiltration was evaluated. Model performance was compared with the European LeukemiaNet (ELN) 2022 genetic risk stratification system. Expression levels of key genes were analyzed in GSE114868 and validated in independent clinical samples.</p><p><strong>Results: </strong>A prognostic risk model was developed based on seven m7G-RGs (<i>TM6SF1, IL1R2, MTX1, SUSD3, SLC22A4, TUBA4A, and RETN</i>). Patients with AML were stratified into high- and low-risk groups, with the low-risk group showing significantly longer overall survival. Compared with the ELN 2022 classification, the model provided significant prognostic refinement within the heterogeneous intermediate-risk subgroup. <i>IL1R2</i> and <i>TUBA4A</i> expression were significantly associated with immune cell infiltration scores. Consistent with the bioinformatics analyses, <i>TM6SF1, IL1R2, MTX1, and SLC22A4</i> expression was significantly reduced in an independent AML cohort and in patient samples compared with controls.</p><p><strong>Conclusion: </strong>We developed and validated a novel m7G-related prognostic model for AML based on seven genes. The findings suggest a potential association among m7G modification, AML prognosis, and the tumor immune microenvironment. The model showed complementary value to the ELN 2022 risk stratification by improving risk assessment among patients classified as intermediate risk. As a retrospective, computational study, prospective validation is required. The identified m7G-RGs warrant further investigation as potential biomarkers or therapeutic targets.</p>","PeriodicalId":42368,"journal":{"name":"Blood and Lymphatic Cancer-Targets and Therapy","volume":"16 ","pages":"575337"},"PeriodicalIF":3.2,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12991311/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147475711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Petroleum Compounds Exposure and Risk of Childhood Leukemia: A Systematic Review.","authors":"Hossam Mohamed Hassan Soliman, Wesal Youssef Hassan, Marwa Mostafa, Mohamed Khamis Gomaa, Mohamed Hossam Soliman Jnr, Mohamed Fakhry Hussein","doi":"10.2147/BLCTT.S571340","DOIUrl":"10.2147/BLCTT.S571340","url":null,"abstract":"<p><p>Childhood leukemia remains a critical public health concern, necessitating comprehensive evaluations of environmental risk factors. This systematic review aims to evaluate the epidemiological evidence regarding the relationship between combined oil exposure during pregnancy and childhood and an increased risk of childhood leukemia, thereby contributing to improved overall childhood health. The review focused on children diagnosed with leukemia. Following the guidelines set forth by the Cochrane Handbook for Systematic Reviews of Interventions' instructions, we conducted a systematic review. Three databases (PubMed, Google Scholar, and Medline) were thoroughly searched to find research that was up to May 31, 2025. Two independent reviewers screened the literature by using Covidence software. The methodological quality and potential for bias in each included case-control and cohort study were systematically evaluated using the Quality Assessment Tool integrated within Covidence software. We assessed the overall quality of evidence using AMSTAR 2, a widely used instrument for critically appraising systematic reviews. In total, 13 studies were included in this review: 11 case-control and 2 cohort studies with an overall sample size of 2,808,870 individuals. Four studies indicated a statistically significant association between maternal and paternal exposure to \"gasoline, benzene, diesel exhaust, oil, mineral oil, and gas\" and an increased likelihood of childhood leukemia. One study indicated that the association with petrol compound exposure appeared stronger for acute myeloid leukemia (AML) than for acute lymphoblastic leukemia (ALL). Multiple studies reported positive associations between different petroleum compound exposures and childhood leukemia. In conclusion, the current review pointed toward an association between exposure to petrol compounds and a higher risk of childhood leukemia. Therefore, we recommend implementing stricter environmental regulations on benzene emissions and establishing evidence-based safety buffer zones between petrol stations and residential areas. Furthermore, routine air quality monitoring near these sites is essential to safeguard pediatric health.</p>","PeriodicalId":42368,"journal":{"name":"Blood and Lymphatic Cancer-Targets and Therapy","volume":"16 ","pages":"571340"},"PeriodicalIF":3.2,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12912160/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146220507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Natural Killer/T-Cell Lymphoma-Associated Hemophagocytic lymphohistiocytosis-a Rare and Dangerous Disease.","authors":"Guangqiang Meng, Manzhi Wang, Congcong Sun, Gege Feng, Jing Ren, Saran Feng, Yan Wang","doi":"10.2147/BLCTT.S574445","DOIUrl":"10.2147/BLCTT.S574445","url":null,"abstract":"<p><p>Hemophagocytic lymphohistiocytosis (HLH) is a clinical syndrome characterised by the reactive activation of cytotoxic T-lymphocytes and macrophages along with a substantial amount of cytokine secretion caused by various inductions. Natural killer/T-cell lymphoma (NKTL)-associated HLH (NK/T-LAHLH) is rare in clinical practice with an incidence rate of 7.1-11.9% in NKTL patients. Currently, there is no standard first-line treatment with good efficacy for NK/T-LAHLH. The treatment of NK/T-LAHLH is still mainly based on chemotherapy regimens containing etoposide and dexamethasone. Recently, many new therapeutic drugs and schemes have been trialled for the treatment of NK/T-LAHLH, such as ruxolitinib, immune checkpoint inhibitors, pegaspargase, and the DEP regimen. However, NK/T-LAHLH is associated with overall poor prognosis. Improving overall understanding of NK/T-LAHLH is of great significance to ameliorating patient prognosis. This review systematically discussed the epidemiology, pathogenesis, clinical features, current treatment regimens, and prognosis of NK/T-LAHLH to comprehensively elucidate this disease.</p>","PeriodicalId":42368,"journal":{"name":"Blood and Lymphatic Cancer-Targets and Therapy","volume":"16 ","pages":"574445"},"PeriodicalIF":3.2,"publicationDate":"2026-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13007379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147515659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Efficacy of Flumatinib in Patients with Chronic Phase Chronic Myeloid Leukemia: A Real-Life Cohort Observational Study.","authors":"Fang Cheng, Zheng Cui, Qiang Li, Liu Wang, Weiming Li","doi":"10.2147/BLCTT.S573070","DOIUrl":"10.2147/BLCTT.S573070","url":null,"abstract":"<p><strong>Background: </strong>This study aims to comprehensively evaluate the safety and effectiveness of flumatinib in both first-line and subsequent-line therapies in 244 chronic-phase chronic myeloid leukemia (CML-CP) patients.</p><p><strong>Methods: </strong>Response criteria were applied according to the European LeukemiaNet. Adverse events (AEs) occurring after flumatinib treatment were documented and graded for severity.</p><p><strong>Results: </strong>The study encompassed 244 patients with CML-CP, stratified by treatment lines: first-line (1L, N=138), second-line (2L, N=63), and third-line or above (≥3L, N=43). First-line flumatinib therapy resulted in a major molecular response achieved by 50.7% at 6 months and 66.7% at 12 months, with a deep molecular response (DMR) achieved by 20.3% at 6 months and 35.5% at 12 months. In subsequent treatment lines, those with baseline MR2 had a DMR rate of 42.9%, compared to 23.3% for those without it. Significant differences in molecular response rates were observed based on treatment line and prior tyrosine kinase inhibitors (TKI) resistance (p<0.05). However, subgroup analyses showed no significant differences in treatment responses between the warning and resistance groups after flumatinib therapy. Dose reduction strategies, implemented in 19.3% of patients, have proven feasible without compromising efficacy. Eight patients subsequently attempted treatment cessation, with five maintaining treatment-free remission. AEs were predominantly grade 1-2, with diarrhea (27.0%), fatigue (12.3%), and thrombocytopenia (11.5%) being the most frequent. Grade 3/4 AEs were infrequent, highlighting flumatinib's manageable safety profile.</p><p><strong>Conclusion: </strong>Flumatinib displays significant clinical efficacy and a superior safety profile compared to other second-generation TKI, whether administered in first-line or subsequent treatment settings.</p>","PeriodicalId":42368,"journal":{"name":"Blood and Lymphatic Cancer-Targets and Therapy","volume":"16 ","pages":"573070"},"PeriodicalIF":3.2,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13007342/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147515597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}